Page 4 - Sight Biologic News Today

Study demonstrates contralateral transfer of LUMEVOQ after unilateral injection Results suggest mechanistic explanation for bilateral improvement of visual function among ND4-LHON patients

December 2, 2021, at 8:00 am EST 2:00 pm CET Connection details for live call and translation provided Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US - read this article along with other careers information, tips and advice on BioSpace

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022 Successful refinancing in Q1 2021 secures mid-2023 runway Multiple regulatory and clinical milestones expected in Q4 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cen...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative

Clinically meaningful difference between visual outcomes of LUMEVOQ®-treated patients and untreated patients Regulatory News: GenSight Biologics ...

Friday June 4th, 2021 8:00 am to 9:00 am EDT Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing

GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch - read this article along with other careers information, tips and advice on BioSpace

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of Françoise de Craecker to its Board of Directors, replacing Natalie Mount. Mrs. de Craecker is joining as an independent Director. “I am thrilled to be joining the GenSight team as they are transforming from an R&D compan...